Query: Inflammatory signaling pathways in IBM skeletal muscle AND specific roles of IL-1β, TNFα, type I interferons, NF-κB activation in myotube dysfunction AND modulation by genetic or pharmacological interventions with impact on contractile performance

Inflammatory signaling in inclusion body myositis (IBM) skeletal muscle involves a complex interplay of cytokines and intracellular pathways that disrupt myotube function and compromise contractile performance. IL-1β, TNFα, type I interferons, and the transcription factor NF-κB play central roles in this process. (OpenTargets Search: inclusion body myositis-IL1B,TNF,IFNA1,IFNB1,NFKB1)

IL-1β is a potent pro-inflammatory cytokine whose expression in IBM is linked with activation of the NLRP3 inflammasome and caspase-1, resulting in its increased secretion. This cytokine not only initiates further inflammatory cascades but also promotes detrimental protein aggregation, notably β-amyloid deposition within muscle fibers, which interferes with proper calcium handling necessary for contraction. (needham2017advancesininclusion pages 12-12)

TNFα is another key modulator in IBM and is expressed both by infiltrating immune cells and by the injured muscle fibers themselves. Its primary mechanism of action in IBM occurs through the activation of NF-κB rather than the MAPK pathways, leading to the transcription of genes that promote muscle atrophy and protein degradation—processes that directly correlate with myotube dysfunction. (needham2017advancesininclusion pages 5-6)

Type I interferons, though less extensively characterized in IBM relative to IL-1β and TNFα, contribute to an amplified immune response by enhancing antigen presentation and further recruitment of inflammatory cells. Their signaling initiates cascades that potentiate the overall inflammatory milieu, indirectly affecting muscle cell function and regenerative capacity. (OpenTargets Search: inclusion body myositis-IL1B,TNF,IFNA1,IFNB1,NFKB1)

NF-κB activation is central to IBM pathology, functioning as a convergence point for upstream signals including IL-1β, TNFα, and even type I interferons. Once activated, NF-κB drives the expression of pro-inflammatory cytokines, chemokines, and atrophy-related genes, thereby fostering chronic inflammation and impairing myotube regeneration essential for maintaining contractile performance. (mccord2023investigatingtheinfluence pages 250-253)

The resultant myotube dysfunction is marked by an imbalance in protein turnover and a disruption of cellular homeostasis driven by the sustained activation of these inflammatory pathways. Increased expression of proteins such as MuRF-1 and MAFbx/Atrogin-1, which are under transcriptional control of NF-κB, leads to muscle fiber degradation and reduced contractile force. (OpenTargets Search: inclusion body myositis-IL1B,TNF,IFNA1,IFNB1,NFKB1)

Pharmacological interventions have targeted these pathways in both preclinical and early experimental studies to restore muscle homeostasis. TNFα inhibitors (e.g., etanercept and infliximab) have been shown to reduce NF-κB activation and decrease markers of muscle atrophy in cellular models, suggesting that modulation of TNFα signaling holds promise for improving myotube function. However, despite demonstrable effects on inflammatory markers, these interventions have yet to significantly enhance overall contractile performance in clinical settings. (mccord2023investigatingtheinfluence pages 246-248)

IL-1 receptor antagonists, such as anakinra, have also been explored with the hypothesis that blocking IL-1β signaling could mitigate muscle inflammation and subsequent degeneration. Preclinical studies indicate that inhibition of the inflammasome and IL-1β signaling dampens inflammatory cascades and reduces proteotoxic stress, yet clinical translation has shown limited efficacy in reversing myotube dysfunction. (guglielmi2024sporadicinclusionbody pages 18-19)

Similarly, genetic interventions aimed at modulating NF-κB activity have demonstrated potential in experimental models by restoring a more balanced inflammatory response and promoting muscle regeneration. Nonetheless, the clinical impact on muscle strength and contractile performance remains to be validated, as there is a distinct gap in ongoing or completed clinical trials specifically targeting these pathways in IBM. (Clinical Trials Search: inclusion body myositis AND (IL-1β OR TNFα OR type I interferon OR NF-κB) AND (genetic OR pharmacological intervention))

In summary, the coordinated activities of IL-1β, TNFα, type I interferons, and NF-κB underpin the inflammatory environment in IBM skeletal muscle, leading to a cascade of events that drive myotube dysfunction, impaired regeneration, and decreased contractile performance. Despite promising preclinical evidence for pharmacological and genetic interventions targeting these pathways, clinical improvements in muscle function have not been firmly established, underscoring the need for further research into effective therapeutic strategies. (guglielmi2024sporadicinclusionbody pages 28-30)

References:
1. (OpenTargets Search: inclusion body myositis-IL1B,TNF,IFNA1,IFNB1,NFKB1): Open Targets Query (inclusion body myositis-IL1B,TNF,IFNA1,IFNB1,NFKB1, 18 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.

2. (guglielmi2024sporadicinclusionbody pages 18-19): Valeria Guglielmi, Marta Cheli, Paola Tonin, and Gaetano Vattemi. Sporadic inclusion body myositis at the crossroads between muscle degeneration, inflammation, and aging. International Journal of Molecular Sciences, 25:2742, Feb 2024. URL: https://doi.org/10.3390/ijms25052742, doi:10.3390/ijms25052742. This article has 8 citations and is from a peer-reviewed journal.

3. (guglielmi2024sporadicinclusionbody pages 28-30): Valeria Guglielmi, Marta Cheli, Paola Tonin, and Gaetano Vattemi. Sporadic inclusion body myositis at the crossroads between muscle degeneration, inflammation, and aging. International Journal of Molecular Sciences, 25:2742, Feb 2024. URL: https://doi.org/10.3390/ijms25052742, doi:10.3390/ijms25052742. This article has 8 citations and is from a peer-reviewed journal.

4. (mccord2023investigatingtheinfluence pages 246-248): B McCord. Investigating the influence of inflammatory mediators on non-inflammatory features of sporadic inclusion body myositis in vitro. Unknown journal, 2023.

5. (mccord2023investigatingtheinfluence pages 250-253): B McCord. Investigating the influence of inflammatory mediators on non-inflammatory features of sporadic inclusion body myositis in vitro. Unknown journal, 2023.

6. (needham2017advancesininclusion pages 12-12): Merrilee Needham and Frank Mastaglia. Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects. Expert Opinion on Orphan Drugs, 5:431-443, Apr 2017. URL: https://doi.org/10.1080/21678707.2017.1318056, doi:10.1080/21678707.2017.1318056. This article has 3 citations.

7. (needham2017advancesininclusion pages 5-6): Merrilee Needham and Frank Mastaglia. Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects. Expert Opinion on Orphan Drugs, 5:431-443, Apr 2017. URL: https://doi.org/10.1080/21678707.2017.1318056, doi:10.1080/21678707.2017.1318056. This article has 3 citations.
